Replies to post #2486 on Biostax Corp (BTAX)

[noreen]

I don't know about the trials you are referring to. In terms of LDN "not helping everybody", that would be true for any drug.

In the clinical trials in Nigeria, they were looking for an increase in CD4 count in at least 25% of the patients taking LDN, and the results showed that 44% of the patients had in increase in CD4 count after taking LDN (I'm pretty sure that's correct, but not 100% sure - or maybe it was that they were looking for a 25% increase in CD4 count and found 44%, I forget exactly). In addition to that, LDN is more effective in treating other diseases besides HIV / AIDS. I believe it is most effect in treating Crohn's disease, with something like a 75% success rate. I believe Cytocom (55% owned by IMUN) has already passed a Phase II trial in the United States with LDN for Crohn's disease. There is info on Cytocom's website about it.

To get an answer to your question, you should contact the company directly, or you might be able to find what you're looking for on www.lowdosenaltrexone.org, but I don't know anything about these trials in England that you're referring to.